Related Experiment Videos
Combined trabeculectomy and extracapsular cataract extraction with mitomycin C
1Department of Ophthalmology, Veterans General Hospital-Taipei, Taiwan, R.O.C.
Zhonghua Yi Xue Za Zhi = Chinese Medical Journal; Free China Ed
|January 24, 1998
Summary
Adjunctive mitomycin C (MMC) in combined trabeculectomy and extracapsular cataract extraction significantly reduces intraocular pressure (IOP) long-term. Most patients achieved target IOP without medication one year post-surgery.
Area of Science:
- Ophthalmology
- Surgical Innovation
Background:
- Evaluating the efficacy of mitomycin C (MMC) as an adjunct in glaucoma surgery.
- Assessing long-term outcomes of combined procedures for cataract and glaucoma.
Purpose of the Study:
- To determine the sustained intraocular pressure (IOP) lowering effect of 0.02% MMC.
- To evaluate the safety profile of MMC in combined trabeculectomy and extracapsular cataract extraction (ECCE).
Main Methods:
- Retrospective analysis of 30 patients undergoing MMC-augmented trabeculectomy and ECCE.
- Minimum follow-up duration of 12 months to assess long-term IOP control and safety.
Main Results:
- Significant IOP reduction from 19.2 mmHg preoperatively to 12.1 mmHg at 1 year (p < 0.001).
- 90% of patients achieved IOP ≤ 15 mmHg, with 86.7% requiring no medication.
- No significant changes in corneal astigmatism or endothelial cell count were observed.
Conclusions:
- Combined trabeculectomy and ECCE with MMC provides effective and sustained IOP reduction.
- Intraoperative MMC (0.02%) is safe, with no adverse effects on corneal endothelium or wound healing.